1. Executive Summary 2. Introduction 2.1 Cancer: An Overview 2.1.1 Cancer: Meaning 2.1.2 Difference Between Normal and Cancer Cells 2.1.3 Types of Cancer 2.1.4 Treatments of Cancer 2.1.5 Classification of Anticancer Drugs 2.1.6 Side Effects of Chemotherapy 3. Global Market Analysis 3.1 Global Cancer Drug Market: An Analysis 3.1.1 Global Cancer Drug Market by Value 3.1.2 Global Cancer Drug Market by Region (China and Rest of the World) 3.2 Global Cancer Drug Market: Product Analysis 3.2.1 Global PD-1 Market by Value 3.2.2 Global PD-1 Market by Type of Product 3.2.3 Global Zanubrutinib (Excluding China) Market by Value 4. China Market Analysis 4.1 China Cancer Drug Market: An Analysis 4.1.1 China Cancer Drug Market by Value 4.1.2 China Cancer Cases 4.1.3 Incidence of Types of Cancer of Cancer of China Out of the World 4.2 China Cancer Drug Market: Product Analysis 4.2.1 China PD-1 Market by Value 4.2.2 China Zanubrutinib Market by Value 5. Market Dynamics 5.1 Growth Drivrs 5.1.1 Rising Aging Population 5.1.2 Rising Incidence Ratio 5.1.3 Stress Resulting in Increasing Cancer Cases 5.1.4 Growing Urban Population 5.1.5 Increasing GNI Per Capita in China 5.1.6 Introduction of Cutting Edge Therapy 5.1.7 Changing Lifestyle and Rising Awareness 5.1.8 Public Medical Insurance 5.2 Challenges 5.2.1 Cross-Border Consultation 5.2.2 Failure of Clinical Trial 5.3 Market Trends 5.3.1 Accelerated Approval for Advanced Cancer Drugs 5.3.2 Combination Therapy 5.3.3 Exemption of Import Tariff on Cancer Drugs 6. Competitive Landscape 6.1 China Cancer Drug Market: Top Players Analysis 7. Company Profiling 7.1 Celgene 7.1.1 Business Overview 7.1.2 Financial Overview 7.1.3 Business Strategy 7.2 Novartis 7.2.1 Business Overview 7.2.2 Financial Overview 7.2.3 Business Strategy 7.3 Roche 7.3.1 Business Overview 7.3.2 Financial Overview 7.3.3 Business Strategy 7.4 Johnson & Johnson 7.4.1 Business Overview 7.4.2 Financial Overview 7.4.3 Business Strategy List of Figures Figure 1: Difference Between Normal and Cancer Cells Figure 2: Types of Cancer Figure 3: Different Treatments of Cancer Figure 4: Classification of Anticancer Drugs Figure 5: Side Effects of Chemotherapy Figure 6: Global Cancer Drug Market by Value; 2015-2017 (US$ Billion) Figure 7: Global Cancer Drug Market by Value; 2018-2022 (US$ Billion) Figure 8: Global Cancer Drug Market by Region (China and Rest of the World); 2017 (Percentage, %) Figure 9: Global PD-1 Market by Value; 2016-2017 (US$ Billion) Figure 10: Global PD-1 Market by Value; 2018-2022 (US$ Billion) Figure 11: Global PD-1 Market by Type of Product; 2016-2017 (US$ Billion) Figure 12: Global Zanubrutinib (Excluding China) Market by Value; 2020-2022 (US$ Million) Figure 13: China Cancer Drug Market by Value; 2011-2017 (US$ Billion) Figure 14: China Cancer Drug Market by Value; 2018-2022 (US$ Billion) Figure 15: China Cancer Cases; 2013-2017 (Million) Figure 16: Incidence of Types of Cancer of China Out of the World ; 2015 Figure 17: China PD-1 Market by Value; 2020-2022 (US$ Billion) Figure 18: China Zanubrutinib Market by Value; 2019-2022 (US$ Million) Figure 19: China Population Above 65 years; 2011-2016 (Billion) Figure 20: China Colorectal Cancer Trend; 2000-2030 Figure 21: Mortality-Incidence Ratio; 2016 Figure 22: Stress and Worry Penetration in Chinese Population; 2011-2016 (Percentage, %) Figure 23: China Urban Population; 2011-2016 (Million) Figure 24: China GNI Per Capita; 2011-2016 (US$) Figure 25: Patients Access to New Oncology Drugs; 2011-2016 (Thousand) Figure 26: Chinese Patients Cross-Border Consultation; 2016 (Percentage,%) Figure 27: Celgene Revenue; 2013-2017 (US$ Billion) Figure 28: Celgene Revenue by Product; 2017 (Percentage, %) Figure 29: Celgene Revenue by Region; 2017 (Percentage, %) Figure 30: Novartis Net Sales; 2013-2017 (US$ Billion) Figure 31: Novartis Net Sales by Segment; 2017 (Percentage, %) Figure 32: Novartis Net Sales by Region; 2017 (Percentage, %) Figure 33: Roche Sales; 2013-2017 (US$ Billion) Figure 34: Roche Sales by Segment; 2017 (Percentage, %) Figure 35: Roche Sales by Region; 2017 (Percentage, %) Figure 36: Johnson & Johnson Sales; 2013-2017 (US$ Billion) Figure 37: Johnson & Johnson Sales by Segment; 2017 (Percentage, %) Figure 38: Johnson & Johnson Sales by Region; 2017 (Percentage, %) Table 1: Types of Cutting Edge Treatments Table 2: Cancer Drugs Approved from the Priority Review List; 2017 Table 3: Expected Sales of Combined Therapies in China; 2021-2025 Table 4: China Cancer Drug Market Player Comparison